MA54595A - Procédé de préparation d'agglomérats sphériques de timapiprant - Google Patents
Procédé de préparation d'agglomérats sphériques de timapiprantInfo
- Publication number
- MA54595A MA54595A MA054595A MA54595A MA54595A MA 54595 A MA54595 A MA 54595A MA 054595 A MA054595 A MA 054595A MA 54595 A MA54595 A MA 54595A MA 54595 A MA54595 A MA 54595A
- Authority
- MA
- Morocco
- Prior art keywords
- timapiprant
- preparing spherical
- spherical agglomerates
- agglomerates
- preparing
- Prior art date
Links
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 title 1
- 229940070124 timapiprant Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18248081 | 2018-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54595A true MA54595A (fr) | 2022-04-06 |
Family
ID=65010443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054596A MA54596A (fr) | 2018-12-27 | 2019-12-19 | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
| MA054595A MA54595A (fr) | 2018-12-27 | 2019-12-19 | Procédé de préparation d'agglomérats sphériques de timapiprant |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054596A MA54596A (fr) | 2018-12-27 | 2019-12-19 | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220184060A1 (fr) |
| EP (2) | EP3902794A1 (fr) |
| MA (2) | MA54596A (fr) |
| WO (2) | WO2020136093A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| US9668975B2 (en) * | 2014-10-14 | 2017-06-06 | PharmaDax Inc. | Method of preparing drug agglomerate |
-
2019
- 2019-12-19 MA MA054596A patent/MA54596A/fr unknown
- 2019-12-19 US US17/421,710 patent/US20220184060A1/en not_active Abandoned
- 2019-12-19 EP EP19832373.5A patent/EP3902794A1/fr not_active Withdrawn
- 2019-12-19 MA MA054595A patent/MA54595A/fr unknown
- 2019-12-19 WO PCT/EP2019/086458 patent/WO2020136093A1/fr not_active Ceased
- 2019-12-19 WO PCT/EP2019/086471 patent/WO2020136095A1/fr not_active Ceased
- 2019-12-19 EP EP19832673.8A patent/EP3902795A1/fr not_active Withdrawn
- 2019-12-19 US US17/421,701 patent/US20220184059A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220184060A1 (en) | 2022-06-16 |
| MA54596A (fr) | 2022-04-06 |
| EP3902795A1 (fr) | 2021-11-03 |
| US20220184059A1 (en) | 2022-06-16 |
| EP3902794A1 (fr) | 2021-11-03 |
| WO2020136093A1 (fr) | 2020-07-02 |
| WO2020136095A1 (fr) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3683205A4 (fr) | Procédé de préparation d'isocyanate aliphatique | |
| EP3376990A4 (fr) | Procédé de confirmation de l'enregistrement d'os sous observation | |
| EP3448918A4 (fr) | Procédé de préparation de résines d'organopolysiloxane | |
| EP3315512A4 (fr) | Procédé pour la préparation sélective d'un conjugué anticorps-médicament | |
| MA53920A (fr) | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 | |
| EP3393647A4 (fr) | Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles | |
| MA51988A (fr) | Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale | |
| MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
| EP3495362A4 (fr) | Dérivé de l'acide thioglycolique imidazopyridine, son procédé de préparation et son application | |
| EP3658552A4 (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| EP3808732A4 (fr) | Procédé de préparation d'isocyanates aliphatiques | |
| EP3712193A4 (fr) | Procédé de préparation d'une polyéthercétonecétone et polyéthercétonecétone ainsi préparée | |
| EP3766869A4 (fr) | Procédé simple de préparation d'avibactam | |
| EP3484347A4 (fr) | Procédé de cartographie du risque d'escarre | |
| MA53370A (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| EP3363466A4 (fr) | Procédé de préparation d'agent de contraste pour imagerie par résonance magnétique | |
| EP3696168A4 (fr) | Procédé de préparation de 2-chloro-5-trifluorométhylpyridine | |
| EP3349592A4 (fr) | Formulation d'os à mâcher pour animal et son procédé de fabrication | |
| EP3415552A4 (fr) | Procédé de préparation d'une résine superabsorbante et résine superabsorbante | |
| EP3902792A4 (fr) | Procédé de préparation d'anthranilamides | |
| EP3722286A4 (fr) | Sel d'un dérivé de phénylpropionamide et son procédé de préparation | |
| EP3533856A4 (fr) | Procédé de préparation d'hexadécahydropyrène | |
| EP3744711A4 (fr) | Procédé de préparation de mesaconine et d'intermédiaires associés | |
| MA50124A (fr) | Procédé de préparation de tubulysines et d'intermédiaires de celles-ci | |
| EP3602036A4 (fr) | Procédé pour la détermination d'amines filmogènes |